2. There are thousands of different abnormalities. From what I understand about the FDA validation process for this sort of thing there would be only 10s of abnormalities. There are likely, many, many of them that are quite obvious to radiologists. And once again, this would be a question that should be studied carefully when people's lives are at risk, instead of just assuming that it will be fine then going ahead to "move fast and break things"
I agree 100% with this, but how can this question be studied of this research to develop these systems doesn't go forward? You earlier characterized the FastMRI research as, in your view, "actually very dangerous." As I see it, the research here is potentially extremely valuable, and the danger comes not from the research, but from somebody deciding to deploy it without considering these questions. Typically the road from research program to wide deployment is quite long, and I disagree that we should discourage the research because of potential flaws in the productization process. (Unless there is ill will on the part of the researchers, which I'm assuming there is not).
The argument that "our system is already bad so we should just merge this new bad component because it doesn't make it worse" is bad in software, and unacceptable in medicine.
If the scanning process has a sensitivity of 99.999%, and the next stage in the signal chain has a sensitivity of 50%, and we consider what happens if the MRI sensitivity drops to 99.9%, that's well in the noise in terms of diagnostic value. Use some of the extra money freed up by doing the MRI 10x faster to pay a radiologist to look at the scan for 10% longer, and perhaps the net accuracy has improved.
What is unacceptable about this kind of holistic reasoning about the system? High performing systems are frequently not composed of perfect components.
Omitting 90% of samples (based on 10x speed claim) leaves an awful lot of room for bizarre errors.
1. If an MRI can be done 10x faster with the same results except in exceptionally rare cases, might that not still be a win? Order of magnitude reduction in time may translate to substantial reduction in cost and increase opportunity for applications. It seems like it is worth considering whether these benefits might be worth compromising the accuracy of the imaging.
2. How accurate are radiologists at diagnosing / detecting these rare abnormalities that validation might miss? If radiologists are actually pretty mediocre at this, might it be OK to make the scan slightly imperfect if the next stage (the human) is already very imperfect?